Clinical Trial Update: IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial comparing IT or IA infusion of PD-1/PD-L1/CTLA-4 inhibitors to standard IV infusion for head and neck cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Head/Neck Neoplasm | Phase 2, Phase 3 | Status: RECRUITING